A Beijing Mabworks Biotech Co. Ltd. patent describes new antibody-drug conjugates (ADCs) comprising antigen-binding fragments or antibodies targeting delta-like protein 3 (DLL3) linked to a cytotoxic drug potentially useful for the treatment of small-cell lung cancer (SCLC).

Beijing Jingwei-Yankang Biomedical Co. Ltd. has reported new phenyl-substituted heterocyclic compounds acting as retinol-binding protein 4 (RBP4) inhibitors with potential in the treatment of age-related macular degeneration (AMD).

KU Leuven and Universität Zürich have discovered new tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and/or tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) inhibitors potentially useful for the treatment of cancer and metabolic diseases.

Pikavation Therapeutics Inc. has patented new phosphatidylinositol 3-kinase α (PI3Kα) inhibitors potentially useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities and PIK3CA-related overgrowth spectrum.

Nurix Therapeutics Inc. has disclosed new proteolysis targeting chimera (PROTAC) compounds potentially useful for the treatment of cancer.

Wigen Biomedicine Technology (Shanghai) Co. Ltd. has synthesized new phosphatidylinositol 3-kinase α (PI3Kα) modulators potentially useful for the treatment of solid tumors and hematological cancers.

China Pharmaceutical University has patented new isochromanone compounds acting as proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitors. As such, they are described as potentially useful for the treatment of atherosclerosis, obesity, hepatic steatosis, hypercholesterolemia, hyperlipidemia and hypertriglyceridemia.

Spark Biopharma Inc. has identified new stimulator of interferon genes protein (STING; TMEM173) agonists potentially useful for the treatment of cancer.

Gilead Sciences Inc. has described new protein mono-ADP-ribosyltransferase TIPARP (PARP-7; ARTD14) inhibitors potentially useful for the treatment of cancer. 100% 10 mM HCl formulation suspension form of an exemplified compound (Ex 13 pg 135, claim 42) exhibited bioavailability (F) of 48% in beagle dog plasma at 30 mg (equiv.)/kg p.o.

Ono Pharmaceutical Co. Ltd. and Vanderbilt University have prepared and tested new prodrugs of potassium channel subfamily K member 10 (TREK2; KCNK10) and member 2 (TREK-1; KCNK2) inhibitors potentially useful for the treatment of cancer, pulmonary fibrosis, neurological disorders and more.